Antinociceptive properties of fadolmidine (MPV-2426), a novel alpha2-adrenoceptor agonist.
暂无分享,去创建一个
[1] M. Scheinin,et al. &agr;2A Adrenoceptors Contribute to Feedback Inhibition of Capsaicin-induced Hyperalgesia , 2004, Anesthesiology.
[2] D. Maxwell,et al. Neurokinin-1 Projection Cells in the Rat Dorsal Horn Receive Synaptic Contacts from Axons That Possess ␣ 2c -adrenergic Receptors , 2003 .
[3] M. Scheinin,et al. The α2A-adrenoceptor subtype is not involved in inflammatory hyperalgesia or morphine-induced antinociception , 2003 .
[4] P. Talke,et al. Effects of intrathecally administered dexmedetomidine, MPV‐2426 and tizanidine on EMG in rats , 2003, Acta anaesthesiologica Scandinavica.
[5] E. Kumamoto,et al. Alpha 2 adrenoceptor-mediated presynaptic inhibition of primary afferent glutamatergic transmission in rat substantia gelatinosa neurons. , 2003, Anesthesiology.
[6] A. Pertovaara,et al. Comparison of the Visceral Antinociceptive Effects of Spinally Administered MPV-2426 (Fadolmidine) and Clonidine in the Rat , 2003, Anesthesiology.
[7] A. Pertovaara,et al. The influence of chemical sympathectomy on pain responsivity and α2-adrenergic antinociception in neuropathic animals , 2002, Neuroscience.
[8] Christopher M. Tan,et al. Heterozygous α2A-adrenergic receptor mice unveil unique therapeutic benefits of partial agonists , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[9] De-Pei Li,et al. Inhibition of Glutamatergic Synaptic Input to Spinal Lamina IIo Neurons by Presynaptic α2-Adrenergic Receptors , 2002 .
[10] L. Stone,et al. alpha(2C)-Adrenergic receptors mediate spinal analgesia and adrenergic-opioid synergy. , 2002, The Journal of pharmacology and experimental therapeutics.
[11] J. Eisenach,et al. alpha2A-adrenoceptor stimulation reduces capsaicin-induced glutamate release from spinal cord synaptosomes. , 2001, The Journal of pharmacology and experimental therapeutics.
[12] A. Basbaum,et al. Contribution of α2 receptor subtypes to nerve injury‐induced pain and its regulation by dexmedetomidine , 2001, British journal of pharmacology.
[13] A. Pertovaara,et al. Selective and segmentally restricted antinociception induced by MPV‐2426, a novel alpha‐2‐adrenoceptor agonist, following intrathecal administration in the rat , 2000, Acta anaesthesiologica Scandinavica.
[14] E. Kalso,et al. Effects of Radolmidine, A Novel &agr;2-Adrenergic Agonist Compared with Dexmedetomidine in Different Pain Models in the Rat , 2000, Anesthesiology.
[15] E. Kalso,et al. The dissociation of sedative from spinal antinociceptive effects following administration of a novel alpha-2-adrenoceptor agonist, MPV-2426, in the locus coeruleus in the rat. , 2000, Acta anaesthesiologica Scandinavica.
[16] A. Pertovaara,et al. The Mechanical Antihyperalgesic Effect of Intrathecally Administered MPV-2426, a Novel &agr;2-Adrenoceptor Agonist, in a Rat Model of Postoperative Pain , 2000, Anesthesiology.
[17] A. Pertovaara,et al. Attenuation of Ascending Nociceptive Signals to the Rostroventromedial Medulla Induced by a Novel &agr;2-Adrenoceptor Agonist, MPV-2426, following Intrathecal Application in Neuropathic Rats , 2000, Anesthesiology.
[18] J. Eisenach,et al. Antinociceptive and hemodynamic effects of a novel alpha2-adrenergic agonist, MPV-2426, in sheep. , 1999, Anesthesiology.
[19] R. Eglen,et al. Assessment of the role of α2‐adrenoceptor subtypes in the antinociceptive, sedative and hypothermic action of dexmedetomidine in transgenic mice , 1997, British journal of pharmacology.
[20] L. Stone,et al. The α2a Adrenergic Receptor Subtype Mediates Spinal Analgesia Evoked by α2 Agonists and Is Necessary for Spinal Adrenergic–Opioid Synergy , 1997, The Journal of Neuroscience.
[21] T. Guo,et al. Substitution of a mutant alpha2a-adrenergic receptor via "hit and run" gene targeting reveals the role of this subtype in sedative, analgesic, and anesthetic-sparing responses in vivo. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[22] Timothy J. Brennan,et al. Characterization of a rat model of incisional pain , 1996, Pain.
[23] E. Mecke,et al. Dissociation of the α 2-adrenergic antinociception from sedation following microinjection of medetomidine into the locus coeruleus in rats , 1994, Pain.
[24] Antti Pertovaara,et al. Antinociception induced by alpha-2-adrenoceptor agonists, with special emphasis on medetomidine studies , 1993, Progress in Neurobiology.
[25] F. M. Clark,et al. Anatomical evidence for genetic differences in the innervation of the rat spinal cord by noradrenergic locus coeruleus neurons , 1992, Brain Research.
[26] Jin Mo Chung,et al. An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat , 1992, PAIN.
[27] E. Kalso,et al. Involvement of supraspinal and spinal segmental alpha-2-adrenergic mechanisms in the medetomidine-induced antinociception , 1991, Neuroscience.
[28] R. Meyer,et al. Topical application of clonidine relieves hyperalgesia in patients with sympathetically maintained pain , 1991, Pain.
[29] E. Perl,et al. Adrenergic excitation of cutaneous pain receptors induced by peripheral nerve injury. , 1991, Science.
[30] W. Willis,et al. Direct catecholaminergic innervation of primate spinothalamic tract neurons , 1990, The Journal of comparative neurology.
[31] H. Proudfit. Pharmacologic evidence for the modulation of nociception by noradrenergic neurons. , 1988, Progress in brain research.
[32] V. Libri,et al. Evidence that locus coeruleus is the site where clonidine and drugs acting at α1‐ and α2‐adrenoceptors affect sleep and arousal mechanisms , 1987 .
[33] G. Nisticó,et al. EVIDENCE THAT LOCUS-COERULEUS IS THE SITE WHERE CLONIDINE AND DRUGS ACTING AT ALPHA-1-ADRENOCEPTOR AND ALPHA-2-ADRENOCEPTOR AFFECT SLEEP AND AROUSAL MECHANISMS , 1987 .
[34] T. Yaksh. Pharmacology of spinal adrenergic systems which modulate spinal nociceptive processing , 1985, Pharmacology Biochemistry and Behavior.
[35] S. Fielding,et al. The dissociation of the antinociceptive effect of clonidine from supraspinal structures , 1979, Neuropharmacology.